MeiraGTx Holdings (MGTX) Non-Current Assets (2017 - 2026)
MeiraGTx Holdings' (MGTX) quarterly Non-Current Assets came in at $152.7 million in Q4 2025, up 4.4% YoY from $146.2 million in Q4 2024, and down 1.69% on a QoQ basis from $155.3 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Non-Current Assets (2017 - 2026) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Non-Current Assets data on file, last reported at $152.7 million in Q4 2025.
- Quarterly Non-Current Assets rose 4.4% year-over-year to $152.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $603.7 million (down 3.01% YoY) and the FY2025 annual result came in at $152.7 million, up 4.4% from the prior year.
- Non-Current Assets fell to $152.7 million in Q4 2025, from $155.3 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $167.1 million in Q4 2023 to a low of -$228.4 million in Q1 2021.
- A 5-year average of $30.7 million and a median of $145.2 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets slumped 45.22% — and 2024, when it surged 235.17%.
- Tracing MGTX's Non-Current Assets over 5 years: stood at $136.9 million in 2021, then climbed by 19.7% to $163.9 million in 2022, then grew by 1.97% to $167.1 million in 2023, then slipped by 12.5% to $146.2 million in 2024, then gained by 4.4% to $152.7 million in 2025.
- The last three Non-Current Assets figures came in at $152.7 million (Q4 2025), $155.3 million (Q3 2025), and $151.6 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | -215.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -215.08 Mn |
| Dec 31, 2025 | 152.67 Mn |
| Sep 30, 2025 | 155.30 Mn |
| Jun 30, 2025 | 151.63 Mn |
| Mar 31, 2025 | 144.13 Mn |
| Dec 31, 2024 | 146.23 Mn |
| Sep 30, 2024 | 160.44 Mn |
| Jun 30, 2024 | 155.88 Mn |
| Mar 31, 2024 | 159.94 Mn |
| Dec 31, 2023 | 167.12 Mn |
| Sep 30, 2023 | 163.66 Mn |
| Jun 30, 2023 | -140.76 Mn |
| Mar 31, 2023 | 166.66 Mn |
| Dec 31, 2022 | 163.90 Mn |
| Sep 30, 2022 | -147.44 Mn |
| Jun 30, 2022 | -96.93 Mn |
| Mar 31, 2022 | -134.36 Mn |
| Dec 31, 2021 | -176.07 Mn |
| Sep 30, 2021 | -172.90 Mn |
| Jun 30, 2021 | -203.86 Mn |